keyword
MENU ▼
Read by QxMD icon Read
search

Everolimus

keyword
https://www.readbyqxmd.com/read/29344373/multianalysis-with-optical-coherence-tomography-and-vasomotion-in-everolimus-eluting-stents-and-everolimus-eluting-biovascular-scaffolds-the-moves-trial
#1
Diego A Arroyo, Sara Schukraft, Zacharenia Kallinikou, Jean-Christophe Stauffer, Gérard Baeriswyl, Jean-Jacques Goy, Mario Togni, Stéphane Cook, Serban Puricel
Aims: To compare endothelium-dependent vasomotor function and vascular healing 15 months after implantation of two new-generation drug-eluting stents and biovascular scaffolds (BVS). Methods and results: A total of 28 patients previously treated with a SYNERGY stent (bioabsorbable polymer everolimus-eluting stents (BP-EES)), a PROMUS stent (persistent polymer everolimus-eluting stents (PP-EES)) or an ABSORB (BVS) underwent control coronary angiography, 15 months after implantation, coupled with optical coherence tomography imaging and supine bicycle exercise...
2018: Open Heart
https://www.readbyqxmd.com/read/29344249/estradiol-suppresses-phosphorylation-of-er%C3%AE-serine-167-through-upregulation-of-pp2a-in-breast-cancer-cells
#2
Takanori Hayashi, Masahiro Hikichi, Jun Yukitake, Nobuhiro Harada, Toshiaki Utsumi
Aromatase inhibitors (AIs) are effective endocrine therapeutics for postmenopausal women with estrogen receptor (ER)α-positive breast cancer. However, the efficacy of the treatment is often limited by the onset of AI resistance, owing to the phosphorylation of ERα serine 167 (Ser167). Previous studies have indicated that hyperactivation of the phosphoinositide-3 kinase/RAC serine/threonine-protein kinase signaling pathway occurs in AI-resistant breast cancer models, which coincides with elevated levels of ERα phosphorylation at Ser167...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29344138/clinical-and-genetic-analysis-of-tuberous-sclerosis-complex-associated-renal-angiomyolipoma-in-chinese-pedigrees
#3
Shuqiang Li, Yushi Zhang, Jinxing Wei, Xuepei Zhang
Tuberous sclerosis complex-associated renal angiomyolipoma (TSC-RAML) confers a high risk of bleeding and even mortality. However, data on TSC-RAML in Chinese pedigrees is extremely lacking. The present study aimed to investigate its clinical and genetic characteristics by obtaining a detailed medical history from 6 probands and their family members, and reassessing blood tests, computed tomography and renal dynamic imaging examinations that were conducted in the TSC-RAML patients. The TSC1/TSC2 mutation was detected in 2 families...
December 2017: Oncology Letters
https://www.readbyqxmd.com/read/29344106/overall-survival-and-progression-free-survival-with-endocrine-therapy-for-hormone-receptor-positive-her2-negative-advanced-breast-cancer-review
#4
REVIEW
Tomás Reinert, Carlos H Barrios
We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer. First-line was defined as treatment for endocrine therapy-naïve advanced breast cancer or advanced disease treated with endocrine therapy in the adjuvant/neoadjuvant setting. Second-line was defined as endocrine therapy for advanced breast cancer following disease progression on endocrine therapy for advanced disease...
November 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29340719/treatment-with-48-mm-everolimus-eluting-stents-procedural-safety-and-12-month-patient-outcome
#5
C K Tan, Z L Tin, M K M Arshad, J K K Loh, F H Jafary, H H Ho, P J L Ong, T Watson
BACKGROUND: Lesion length is a major predictor of adverse outcomes after percutaneous coronary intervention. Long lesions often require multiple stents with variable overlap, which increases the probability of geographical miss and the incidence of mechanical complications, such as side-branch occlusion, restenosis, and stent thrombosis. These pitfalls may be avoided by use of an ultra-long device. METHODS: We retrospectively assessed the performance of the 48-mm Xience Xpedition everolimus-eluting stent (EES) at our institution...
January 16, 2018: Herz
https://www.readbyqxmd.com/read/29340502/recurrence-of-retroperitoneal-localized-perivascular-epithelioid-cell-tumor-two-years-after-initial-diagnosis-case-report
#6
Yasemin Benderli Cihan, Engin Kut, Ali Koç
CONTEXT: Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors. Adjuvant radiotherapy and/or chemotherapy are administered according to the patient's clinical characteristics. CASE REPORT: A 42-year-old female patient was operated to treat a retroperitoneal mass. The diagnosis was established as PEComa with benign behavior. Two years after the diagnosis, chest and abdominal computed tomography scans showed intra-abdominal recurrence and lymphangioleiomyomatosis in the lung...
January 15, 2018: São Paulo Medical Journal, Revista Paulista de Medicina
https://www.readbyqxmd.com/read/29326972/aggressive-neuroendocrine-tumor-of-the-ovary-with-multiple-metastases-treated-with-everolimus-a-case-report
#7
Michiko Kaiho-Sakuma, Masafumi Toyoshima, Mika Watanabe, Asami Toki, Satomi Kameda, Takamichi Minato, Hitoshi Niikura, Nobuo Yaegashi
•Neuroendocrine tumors (NETs) frequently occur in the lungs or the gastrointestinal tract; they are uncommon in the ovary.•The mammalian target of rapamycin (mTOR) pathway has been reported as a treatment for advanced NETs.•We describe a patient with an aggressive primary ovarian NET, successfully treated with everolimus (an mTOR inhibitor).
February 2018: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/29326152/decision-analytic-markov-model-weighting-expected-benefits-and-current-limitations-of-first-generation-bioresorbable-vascular-scaffolds-implications-for-manufacturers-and-next-device-iterations
#8
Davide Capodanno, Sergio Buccheri, Sara Romano, Piera Capranzano, Bruno Francaviglia, Corrado Tamburino
BACKGROUND: Relative benefits of bioresorbable vascular scaffolds (BVS) compared with everolimus-eluting stents (EES) are expected to accrue after complete bioresorption. METHODS AND RESULTS: We built a decision analytic Markov model comparing BVS and EES for a contemporary percutaneous coronary intervention population. Procedure-related morbidity and outcome data from the available literature were used to derive model probabilities. The net benefit of BVS and EES was estimated in terms of quality-adjusted life expectancy...
January 2018: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29326066/novel-everolimus-loaded-nanocarriers-for-topical-treatment-of-murine-experimental-autoimmune-uveoretinitis-eau
#9
Maren Kasper, Doris Gabriel, Michael Möller, Dirk Bauer, Lena Wildschütz, Herve Courthion, Michael R R Böhm, Martin Busch, Karin Loser, Solon Thanos, Robert Gurny, Arnd Heiligenhaus
In the present study, therapeutic effect of topically applied everolimus (EV)-loaded methoxy-poly(ethylene-glycol)-hexyl substituted poly (lactic acid) (mPEGhexPLA) nanocarriers on experimental autoimmune uveitis (EAU) were investigated. EAU was induced in B10.RIII mice via immunization with human interphotoreceptor retinoid-binding protein peptide 161-180 (hIRBPp161-180) in complete Freund's adjuvant. Everolimus-loaded mPEGhexPLA (EV/mPEGhexPLA) nanocarriers were prepared by using a solvent evaporation method...
January 8, 2018: Experimental Eye Research
https://www.readbyqxmd.com/read/29318464/early-vascular-responses-to-everolimus-eluting-cobalt-chromium-stent-in-the-culprit-lesions-of-st-elevation-myocardial-infarction-results-from-a-multicenter-prospective-optical-coherence-tomography-study-mechanism-ami-2-week-follow-up-study
#10
Yoshihiro Morino, Daisuke Terashita, Hiromasa Otake, Tatsuo Kikuchi, Tetsuya Fusazaki, Nehiro Kuriyama, Takahide Suzuki, Yoshiaki Ito, Kiyoshi Hibi, Hiroyuki Tanaka, Shozo Ishihara, Toru Kataoka, Takashi Morita, Yoritaka Otsuka, Takatoshi Hayashi, Kengo Tanabe, Toshiro Shinke
The use of cobalt-chromium everolimus-eluting stents (CoCr-EES) for ST-segment elevation myocardial infarction (STEMI) reduces the incidence of stent thrombosis compared with bare metal stents, and a substantial difference is apparent in the initial 2 weeks. However, vascular behavior during this early period remains unclear. This was a prospective study (MECHANISM-AMI-2W) to investigate early vascular responses in STEMI patients immediately after CoCr-EES implantation and at 2-week follow-up using frequency domain-optical coherence tomography (FD-OCT)...
January 9, 2018: Cardiovascular Intervention and Therapeutics
https://www.readbyqxmd.com/read/29311077/posaconazole-tablets-in-real-life-lung-transplantation-impact-on-exposure-drug-drug-interactions-and-drug-management-in-lung-transplanted-patients-including-cystic-fibrosis
#11
Manon Launay, Antoine Roux, Laurence Beaumont, Benoit Douvry, Lucien Lecuyer, Emmanuel Douez, Clément Picard, Dominique Grenet, Vincent Jullien, Véronique Boussaud, Romain Guillemain, Eliane M Billaud
Appropriate exposure to Posaconazole (PSZ) was limited since the recent approval of the delayed release oral tablet formulation. Our goal was to determine the exposure obtained by using the standard dose of 300mgx1 in lung transplant patients (LT) including cystic fibrosis (CF) background.PSZ trough concentrations (C0) were determined using LCMS assay. Indicative thresholds of interest were <0.7mg/L (prophylaxis) and 1-3mg/L (curative). Tacrolimus (TRL) and everolimus (ERL) C0 measured during PSZ exposure were collected...
January 8, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29310385/risk-of-gastrointestinal-toxicities-with-pd-1-inhibitors-in-cancer-patients-a-meta-analysis-of-randomized-clinical-trials
#12
Wei Wei, Zhibin Luo
BACKGROUND: Anti-programmed cell death protein 1 (PD-1) antibodies have demonstrated significant clinical activity in many cancer entities. Gastrointestinal toxicities are one of its major side effects, but the overall risks have not been systematically evaluated. Thus, the purpose of this study was to evaluate the incidence and risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients through a meta-analysis. METHODS: Eligible studies were searched for in PubMed, Embase, and the Cochrane Library...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29309638/congress-of-neurological-surgeons-systematic-review-and-evidence-based-guidelines-on-emerging-therapies-for-the-treatment-of-patients-with-vestibular-schwannomas
#13
Jamie J Van Gompel, Siviero Agazzi, Matthew L Carlson, Dare A Adewumi, Constantinos G Hadjipanayis, Joon H Uhm, Jeffrey J Olson
Target Population: Adults with histologically proven or suspected vestibular schwannomas with neurofibromatosis type 2 (NF2). Question: What is the role of bevacizumab in the treatment of patients with vestibular schwannomas? Recommendations: Level 3: It is recommended that bevacizumab be administered in order to radiographically reduce the size or prolong tumor stability in patients with NF2 without surgical options. Level 3: It is recommended that bevacizumab be administered to improve hearing or prolong time to hearing loss in patients with NF2 without surgical options...
December 20, 2017: Neurosurgery
https://www.readbyqxmd.com/read/29309249/cabozantinib-a-new-standard-of-care-for-patients-with-advanced-renal-cell-carcinoma-and-bone-metastases-subgroup-analysis-of-the-meteor-trial
#14
Bernard Escudier, Thomas Powles, Robert J Motzer, Thomas Olencki, Osvaldo Arén Frontera, Stephane Oudard, Frederic Rolland, Piotr Tomczak, Daniel Castellano, Leonard J Appleman, Harry Drabkin, Daniel Vaena, Steven Milwee, Jillian Youkstetter, Julie C Lougheed, Sergio Bracarda, Toni K Choueiri
Purpose Cabozantinib, an inhibitor of tyrosine kinases including MET, vascular endothelial growth factor receptors, and AXL, increased progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with advanced renal cell carcinoma (RCC) after previous vascular endothelial growth factor receptor-targeted therapy in the phase III METEOR trial. Because bone metastases are associated with increased morbidity in patients with RCC, bone-related outcomes were analyzed in METEOR...
January 8, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29306512/erratum-to-checkmate-025-randomized-phase-3-study-outcomes-by-key-baseline-factors-and-prior-therapy-for-nivolumab-versus-everolimus-in-advanced-renal-cell-carcinoma-eur-urol-2017-72-962-71
#15
Bernard Escudier, Padmanee Sharma, David F McDermott, Saby George, Hans J Hammers, Sandhya Srinivas, Scott S Tykodi, Jeffrey A Sosman, Giuseppe Procopio, Elizabeth R Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katriina Peltola, John Wagstaff, Thomas C Gauler, Takeshi Ueda, Huanyu Zhao, Ian M Waxman, Robert J Motzer
No abstract text is available yet for this article.
January 3, 2018: European Urology
https://www.readbyqxmd.com/read/29301825/genomic-correlates-of-response-to-everolimus-in-aggressive-radioiodine-refractory-thyroid-cancer-a-phase-ii-study
#16
Glenn J Hanna, Naifa L Busaidy, Nicole G Chau, Lori J Wirth, Justine A Barletta, Antonio Calles, Robert I Haddad, Stefan Kraft, Maria E Cabanillas, Guilherme Rabinowits, Anne O'Neill, Sewanti A Limaye, Erik K Alexander, Francis D Moore, Krzysztof Misiukiewicz, Tom Thomas, Matthew A Nehs, Ellen Marqusee, Stephanie L Lee, Pasi A Janne, Jochen H Lorch
PURPOSE: Targeting mutations leading to PI3K/mTOR/Akt activation are of interest in thyroid cancer (TC). We evaluated the efficacy of everolimus in aggressive, radioactive iodine refractory (RAIR) TC and correlated tumor mutational profiling with response. Exploratory medullary and anaplastic TC cohorts were included. EXPERIMENTAL DESIGN: This single-arm, multi-institutional phase II study was conducted from 2009-2013 in patients with incurable RAIR TC who had radiographic progression six months prior to enrollment...
January 4, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29299126/hdac-inhibition-as-a-treatment-concept-to-combat-temsirolimus-resistant-bladder-cancer-cells
#17
Eva Juengel, Ramin Najafi, Jochen Rutz, Sebastian Maxeiner, Jasmina Makarevic, Frederik Roos, Igor Tsaur, Axel Haferkamp, Roman A Blaheta
Introduction: Although the mechanistic target of rapamycin (mTOR) might be a promising molecular target to treat advanced bladder cancer, resistance develops under chronic exposure to an mTOR inhibitor (everolimus, temsirolimus). Based on earlier studies, we proposed that histone deacetylase (HDAC) blockade might circumvent resistance and investigated whether HDAC inhibition has an impact on growth of bladder cancer cells with acquired resistance towards temsirolimus. Results: The HDAC inhibitor valproic acid (VPA) significantly inhibited growth, proliferation and caused G0/G1 phase arrest in RT112res and UMUC-3res...
December 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/29296616/everolimus-for-treatment-of-tuberous-sclerosis-complex-associated-neuropsychiatric-disorders
#18
Darcy A Krueger, Anjali Sadhwani, Anna W Byars, Petrus J de Vries, David N Franz, Vicky H Whittemore, Rajna Filip-Dhima, Donna Murray, Kush Kapur, Mustafa Sahin
Objective: To evaluate if short-term treatment with everolimus was safe and could improve neurocognition and behavior in children with TSC. Methods: This was a prospective, double-blind randomized, placebo-controlled two-center phase II study. Participants diagnosed with TSC and age 6-21 years were treated with 4.5 mg/m2 per day of oral everolimus (n = 32) or matching placebo (n = 15) taken once daily for 6 months. For efficacy, a comprehensive neurocognitive and behavioral evaluation battery was performed at baseline, 3 months, and 6 months...
December 2017: Annals of Clinical and Translational Neurology
https://www.readbyqxmd.com/read/29287894/-monitoring-of-hypertension-in-patients-orally-treated-by-angiogenesis-inhibitor-in-daily-practice
#19
Lisa Belaid, Sahar Bayat-Makoei, Brigitte Laguerre, Cécile Vigneau
OBJECTIVE: The aim of this study is to measure the monitoring and the incidence of renovascular effects of angiogenesis inhibitors in real population. METHOD: Are included in this descriptive, monocentric, practical study, patients of 18 years old and more, orally treated by angiogenesis inhibitors and monitored in consultation by clinician nurses. The main interest variable is the incidence of hypertension at three months of treatment. RESULTS: From January, 2011 to July, 2014, 324 patients have been included, whose 53% are men...
December 26, 2017: Néphrologie & Thérapeutique
https://www.readbyqxmd.com/read/29285223/a-carp-1-functional-mimetic-loaded-vitamin-e-tpgs-micellar-nano-formulation-for-inhibition-of-renal-cell-carcinoma
#20
Vino T Cheriyan, Hashem O Alsaab, Sreeja Sekhar, Caitlin Stieber, Prashant Kesharwani, Samaresh Sau, Magesh Muthu, Lisa A Polin, Edi Levi, Arun K Iyer, Arun K Rishi
Current treatments for Renal Cell Carcinoma (RCC) include a combination of surgery, targeted therapy, and immunotherapy. Emergence of resistant RCCs contributes to failure of drugs and poor prognosis, and thus warrants development of new and improved treatment options for RCCs. Here we generated and characterized RCC cells that are resistant to Everolimus, a frontline mToR-targeted therapy, and tested whether our novel class of CARP-1 functional mimetic (CFM) compounds inhibit parental and Everolimus-resistant RCC cells...
December 1, 2017: Oncotarget
keyword
keyword
932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"